Get the Stockscreener App
2.68
10.29%
0.25
Armata Pharmaceuticals Inc stock is traded at $2.68, with a volume of 14,982.
It is up +10.29% in the last 24 hours and up +14.04% over the past month.
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections in the United States. The company develops its products using its proprietary bacteriophage-based technology. Its product candidate is the AP-SA01 that targets Staphylococcus aureus, including multidrug-resistant strains. The company is also developing and advancing synthetic phage for treating diseases caused by pseudomonas aeruginosa. Armata Pharmaceuticals, Inc. is headquartered in Marina del Rey, California.
See More
Previous Close:
$2.43
Open:
$2.45
24h Volume:
14,982
Relative Volume:
0.07
Market Cap:
$97.10M
Revenue:
-
Net Income/Loss:
$-41.36M
P/E Ratio:
-1.6341
EPS:
-1.64
Net Cash Flow:
$-42.09M
1W Performance:
+5.10%
1M Performance:
+14.04%
6M Performance:
+27.32%
1Y Performance:
+21.27%
1-Day Range:
$2.45
$2.68
1-Week Range:
$2.43
$2.72
52-Week Range:
$0.8981
$2.96
Armata Pharmaceuticals Inc Stock (ARMP) Company Profile
Name
Armata Pharmaceuticals Inc
Sector
Industry
Phone
310-655-2928
Address
4503 Glencoe Avenue, Marina del Rey, CA
Compare ARMP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARMP
Armata Pharmaceuticals Inc
|
2.68 | 94.56M | 0 | -41.36M | -42.09M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Armata Pharmaceuticals Inc Stock (ARMP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-19-19 | Initiated | Ladenburg Thalmann | Buy |
Armata Pharmaceuticals Inc Stock (ARMP) Latest News
Is Armata Pharmaceuticals Inc. trending in predictive chart modelsBear Alert & AI Powered Buy/Sell Recommendations - Newser
Is this a good reentry point in Armata Pharmaceuticals Inc.Profit Target & Accurate Intraday Trading Signals - Newser
Multi asset correlation models including Armata Pharmaceuticals Inc.Product Launch & Real-Time Volume Analysis Alerts - Newser
Applying Elliott Wave Theory to Armata Pharmaceuticals Inc.July 2025 Market Mood & Safe Entry Momentum Tips - Newser
What’s the recovery path for long term holders of Armata Pharmaceuticals Inc.July 2025 Highlights & Real-Time Buy Signal Notifications - Newser
How to recover losses in Armata Pharmaceuticals Inc. stockEarnings Growth Report & Free Expert Verified Stock Movement Alerts - Newser
Is Armata Pharmaceuticals Inc. still worth holding after the dip2025 Investor Takeaways & Target Return Focused Picks - Newser
Analyzing net buyer seller activity in Armata Pharmaceuticals Inc.Portfolio Value Report & Growth Focused Entry Reports - Newser
Advanced analytics toolkit walkthrough for Armata Pharmaceuticals Inc.2025 Risk Factors & Technical Buy Zone Confirmations - Newser
Published on: 2025-08-19 17:03:43 - Newser
What technical models suggest about Armata Pharmaceuticals Inc.’s comebackPortfolio Gains Report & Consistent Income Trade Ideas - Newser
What institutional flow reveals about Armata Pharmaceuticals Inc.July 2025 Gainers & Technical Entry and Exit Tips - Newser
Can machine learning forecast Armata Pharmaceuticals Inc. recovery2025 Performance Recap & Real-Time Buy Signal Notifications - Newser
Will Armata Pharmaceuticals Inc. stock benefit from interest rate changesTrade Risk Assessment & Free High Return Stock Watch Alerts - Newser
Automated trading signals detected on Armata Pharmaceuticals Inc.Forecast Cut & Daily Entry Point Trade Alerts - Newser
Tools to assess Armata Pharmaceuticals Inc.’s risk profileProfit Target & Stepwise Entry/Exit Trade Alerts - Newser
Can swing trading help recover from Armata Pharmaceuticals Inc. losses - Newser
Is Armata Pharmaceuticals Inc. forming a reversal patternWeekly Investment Summary & AI Optimized Trading Strategy Guides - Newser
Using RSI to spot recovery in Armata Pharmaceuticals Inc.Quarterly Growth Report & Accurate Trade Setup Notifications - Newser
Using economic indicators to assess Armata Pharmaceuticals Inc. potentialJuly 2025 Analyst Calls & Free Accurate Trade Setup Notifications - Newser
Statistical indicators supporting Armata Pharmaceuticals Inc.’s strengthTrend Reversal & Expert Verified Stock Movement Alerts - Newser
Key metrics from Armata Pharmaceuticals Inc.’s quarterly dataMarket Performance Recap & Technical Confirmation Trade Alerts - Newser
Combining machine learning predictions for Armata Pharmaceuticals Inc.2025 Market WrapUp & Weekly Chart Analysis and Guides - Newser
Short interest data insights for Armata Pharmaceuticals Inc.2025 Market Outlook & Real-Time Market Trend Scan - Newser
What data driven models say about Armata Pharmaceuticals Inc.’s futureQuarterly Market Review & Momentum Based Trading Signals - Newser
How cyclical is Armata Pharmaceuticals Inc.’s revenue streamWeekly Trade Recap & Short-Term Swing Trade Alerts - thegnnews.com
Is Armata Pharmaceuticals Inc. stock overvalued or fairly pricedTrend Reversal & Free Real-Time Market Sentiment Alerts - thegnnews.com
All You Need to Know About Armata Pharmaceuticals (ARMP) Rating Upgrade to Buy - MSN
Using portfolio simulators with Armata Pharmaceuticals Inc. includedMarket Volume Summary & Free Technical Pattern Based Buy Signals - Newser
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Trading 0.8% Higher – Should You Buy? - Defense World
What makes Armata Pharmaceuticals Inc. stock price move sharplyEarnings Recap Summary & Consistent Income Trade Ideas - Newser
Q3 EPS Estimate for Armata Pharmaceuticals Lifted by Analyst - Defense World
Armata Pharmaceuticals Inc Stock (ARMP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):